Oxford Biomedica

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

AnalystConsensusTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

09 May 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

UK£5.08

0.5% undervalued

15 Aug

UK£5.05

45.3%

14.0%

Author's Valuation

UK£5.1

0.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

UK£5.1

0.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.05%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.99%

Calculation

UK£16.06m

Earnings '28

41.93x

PE Ratio '28

UK£673.28m

Market Cap '28

UK£673.28m

Market Cap '28

107.95m

No. shares '28

UK£6.24

Share Price '28

UK£6.24 Share Price '28

Discounted to 2025 @ 7.08% p.a.

UK£5.08

Fair Value '25